SPONSOR
Boryung Pharmaceutical Co., Ltd
Total Trials
2
Recruiting
2
Phases
N/A
Boryung Pharmaceutical Co., Ltd is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Type 2 Diabetes, Diabetes Mellitus, Hypertension.
Studies span multiple clinical phases, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Boryung Pharmaceutical Co., Ltd
How many clinical trials has Boryung Pharmaceutical Co., Ltd sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Boryung Pharmaceutical Co., Ltd, of which 2 are actively recruiting participants. These trials cover conditions including Type 2 Diabetes, Diabetes Mellitus, Hypertension. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Boryung Pharmaceutical Co., Ltd research focus on?
Boryung Pharmaceutical Co., Ltd clinical trials span Type 2 Diabetes, Diabetes Mellitus, Hypertension. Sponsor focus areas evolve as trials complete and new programs launch.
How do I participate in a Boryung Pharmaceutical Co., Ltd clinical trial?
To participate in a Boryung Pharmaceutical Co., Ltd trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Boryung Pharmaceutical Co., Ltd trials with current recruitment status updated daily.
Clinical Trials by Boryung Pharmaceutical Co., Ltd
NCT06649162
Recruiting
A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy
Type 2 Diabetes
NCT05970237
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Diabetes Mellitus
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology